决奈达隆的电生理与临床应用进展

李景东; 夏超睿; 陈媛

doi:10.13201/j.issn.1001-1439.2022.03.002

决奈达隆的电生理与临床应用进展

- 华中科技大学同济医学院附属协和医院心内科(武汉，430022)
基金项目:
国家自然科学基金项目(No：81873476)

详细信息

通讯作者: 李景东，E-mail：jingdong-li@mail.hust.edu.cn

中图分类号: R541.7

收稿日期: 2022-01-10

刊出日期: 2022-03-13

Progress of electrophysiology and the clinical application of dronedarone

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: LI Jingdong, E-mail: jingdong-li@mail.hust.edu.cn

Received Date: 10 January 2022

Publish Date: 13 March 2022

摘要

摘要: 决奈达隆是非碘化的苯并呋喃衍生物，其化学结构与胺碘酮类似。决奈达隆作为一种新型的抗心律失常药物，具有多通道阻滞的作用，它既保留了胺碘酮的疗效，又具有更高的安全性。其有效性和安全性经多个临床试验证实后，于2009年被FAD批准用于心房颤动患者复律后窦性心律的维持。本文就决奈达隆的电生理与临床应用进展作扼要介绍。
- 决奈达隆 /
- 电生理 /
- 心房颤动
Abstract: Dronedarone is a non-iodized benzofuran derivative with a chemical structure similar to amiodarone. As a new antiarrhythmic drug, dronedarone can block multi-channels. It not only retains the efficacy of amiodarone, but also has higher safety. Dronedarone maintains sinus heart rate in patients with atrial fibrillation after cardioversion. Multiple clinical trials confirmed dronedarone's efficacy and safety. So dronedarone was approved by FAD in 2009. This comment briefly introduces the progress of electrophysiology and the clinical application of dronedarone.
- dronedarone /
- electrophysiology /
- atrial fibrillation

HTML全文

参考文献(24)

[1]	Heijman J, Hohnloser SH, Camm AJ. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future[J]. Europace, 2021, 23(23 Suppl 2): ii14-ii22. doi: 10.1093/europace/euaa426
[2]	Hartmann N, Mason FE, Braun I, et al. The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology[J]. J Mol Cell Cardiol, 2016, 94: 95-106. doi: 10.1016/j.yjmcc.2016.03.012
[3]	Yu Y, Luo D, Li Z, et al. Inhibitory Effects of dronedarone on small conductance calcium activated potassium channels in patients with chronic atrial fibrillation: comparison to amiodarone[J]. Med Sci Monit, 2020, 26: e924215. doi: 10.12659/MSM.924215
[4]	Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J, 2021, 42(5): 373-498.
[5]	Boriani G, Blomström-Lundqvist C, Hohnloser SH, et al. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation[J]. Europace, 2019, 21(12): 1764-1775.
[6]	Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin k oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation[J]. JAMA, 2017, 318(13): 1250-1259. doi: 10.1001/jama.2017.13883
[7]	Thind M, Crijns HJ, Naccarelli GV, et al. Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials[J]. J Cardiovasc Electrophysiol, 2020, 31(5): 1022-1030. doi: 10.1111/jce.14405
[8]	Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the control of ventricular rate during atrial fibrillation(ERATO)study[J]. Am Heart J, 2008, 156(3): 527. e521-529. doi: 10.1016/j.ahj.2008.06.010
[9]	Khachatryan A, Merino JL, de Abajo FJ, et al. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice(EFFECT-AF)[J]. Europace, 2021, DOI: 10.1093/europace/euab262.
[10]	Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med, 2009, 360(7): 668-678. doi: 10.1056/NEJMoa0803778
[11]	Goehring ELJr., Bohn RL, Pezzullo J, et al. Outcomes associated with dronedarone use in patients with atrial fibrillation[J]. Am J Cardiol, 2020, 135: 77-83. doi: 10.1016/j.amjcard.2020.08.026
[12]	Lee SR, Choi EK, Kim JH, et al. Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study[J]. Sci Rep, 2020, 10(1): 16102. doi: 10.1038/s41598-020-73115-y
[13]	Goette A, Benninger G, Pittrow D, et al. One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care[J]. Herzschrittmacherther Elektrophysiol, 2015, 26(2): 148-154. doi: 10.1007/s00399-015-0360-z
[14]	Lin JL, Wu TJ, Chen CP, et al. Observational study of dronedarone in Taiwanese patients with atrial fibrillation[J]. J Formos Med Assoc, 2020, 119(1 Pt 1): 59-68.
[15]	Quintana-Villamandos B, Pazó-Sayós L, Arribas SM, et al. Dronedarone induces regression of coronary artery remodeling related to better global antioxidant status[J]. Hypertens Res, 2019, 42(10): 1485-1494. doi: 10.1038/s41440-019-0257-z
[16]	Pisters R, Hohnloser SH, Connolly SJ, et al. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial[J]. Europace, 2014, 16(2): 174-181. doi: 10.1093/europace/eut293
[17]	Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter[J]. Circulation, 2009, 120(13): 1174-1180. doi: 10.1161/CIRCULATIONAHA.109.875252
[18]	Ehrlich JR, Look C, Kostev K, et al. Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany[J]. Int J Cardiol, 2019, 278: 126-132. doi: 10.1016/j.ijcard.2018.11.133
[19]	Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY Trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism[J]. Circ Arrhythm Electrophysiol, 2015, 8(5): 1048-1056. doi: 10.1161/CIRCEP.115.002856
[20]	Friberg L. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs[J]. Am Heart J, 2018, 205: 118-127. doi: 10.1016/j.ahj.2018.06.018
[21]	Frutos-López M, Pedrote A, Acosta-Martínez J, et al. Dramatic reduction of ventricular tachycardia burden after dronedarone plus mexiletine treatment in a patient refractory to hybrid ablation[J]. Rev Port Cardiol(Engl Ed), 2020, 39(3): 171-173. doi: 10.1016/j.repc.2017.11.018
[22]	Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias[J]. Pharmacol Res, 2020, 151: 104521. doi: 10.1016/j.phrs.2019.104521
[23]	Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure[J]. N Engl J Med, 2008, 358(25): 2678-2687. doi: 10.1056/NEJMoa0800456
[24]	Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation[J]. N Engl J Med, 2011, 365(24): 2268-2276. doi: 10.1056/NEJMoa1109867